Xu et al.[32] found that the intestinal contents of IL-17, IL-6 and TNF-α increased significantly in WAS rats, and were reduced after rifaximin treatment, while the contents of IL-10, IFN-1β and IFN-γ remained unchanged before and after WAS intervention. The gene discussed is IL17A; the disease is Wiskott-Aldrich syndrome.